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Abstract
Purpose To determine whether persisting cervical
fluorodeoxyglucose (FDG) uptake after concurrent chemora-
diotherapy (CCRT) for cervical cancer can reflect residual
malignancy.
Methods F-FDG PET/CT was performed before and after
CCRT in 136 patients with cervical cancer. The maximum
and mean standardized uptake values (SUVmax and
SUVmean) were recorded from PET/CT scans performed
pre- and post-treatment. SUVs were correlated with treatment
response after CCRT. Final treatment response was deter-
mined by MRI and further follow-up PET/CT. One hundred
four of 136 patients underwent pelvic MRI, and 32 of 136
patients underwent further follow-up PET/CT. Patients were
classified into two categories: patients with residual tumor or
patients without residual tumor (complete responder). Pre-
and post-treatment serum squamous cell carcinoma antigen
(SCC) levels were also recorded for comparison. The optimal
cutoff value of SUVmax for predicting residual cervical tumor
was determined using receiver-operating characteristic (ROC)
analysis.
Results Of 136 patients, 124 showed complete response on
further follow-up studies and 12 were confirmed to have
residual tumor. The post-treatment SUVmax and pre-/post-
treatment SUVmean of complete responders were significant-
ly lower than those of patients with residual tumor: 2.5±0.8
and 7.2±4.2/1.9±0.7 for complete responders and 5.7±2.6
and 12.8±6.9/3.7±0.7 for patients with residual tumor (p <
0.05). The pre-treatment SUVmax and pre-/post-treatment
serum SCC levels of the complete responders tended to be
lower than those of patients with residual tumor, but this did
not have statistical significance. Using ROC analysis, an
optimal cutoff SUVmax of 4.0 on the post-treatment PET/
CT yielded a sensitivity, specificity, positive predictive value,
and negative predictive value of 92 %, 94 %, 61 %, and 99 %,
respectively (p <0.001).
Conclusions Persistent cervical FDG uptake in18F-FDG PET/
CT after CCRT for cervical cancer may be caused by residual
tumor or post-therapy inflammation. A higher cutoff SUVmax
than conventional criteria for cervical cancer in post-CCRT
PET/CT might help to detect residual tumor.
Keywords Cervical cancer . PET/CT . CCRT . Treatment
response
Introduction
Cervical carcinoma is the third most common gynecologic ma-
lignancy [1]. Clinical staging of cervical cancer is based on the
International Federation of Gynecology and Obstetrics (FIGO)
system, which was revised in 2009 [2]. Although clinical staging
is based on physical examination and limited radiographic eval-
uation, magnetic resonance image (MRI) and computed tomog-
raphy (CT) are important to assess local extracervical spread and
to determine lymph node involvement. Positron emission
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tomography (PET) using 18F-fluorodeoxyglucose (FDG) is also
important to evaluate the metabolic status of cervical cancer [3].
For locally advanced cervical cancer, concurrent chemora-
diotherapy (CCRT) is currently the standard treatment modal-
ity [4]. Disease recurrences develop in approximately one-
third of cervical cancers, and the majority of the recurrences
occur within the first 2 years after completion of treatment [5].
Clinical stage and lymph node status at the time of initial
diagnosis are predictors for disease recurrence [6, 7]. In addi-
tion, presence of persistent tumor lesions on clinical examina-
tion performed 1 to 3 months after treatment is associated with
an elevated recurrence rate [8]. Thus, assessment of the resid-
ual tumor burden is an important factor in the clinical evalu-
ation of cervical cancer therapeutics [9].
18F-FDG PETand PET/CT have been accepted as valuable
tools in the determination of the cervical cancer stage and
detection of disease recurrence [10–13]. Moreover, PET/CT is
useful for the assessment of treatment response of locally
advanced disease [3]. Several studies have reported an asso-
ciation of post-treatment PET/CT with tumor response and
survival in cervical cancer; persistent significant FDG uptake
after treatment has been shown to be predictive of a poor
survival outcome [8, 14, 15]. However, to the best of our
knowledge, the optimal cutoff value of FDG uptake to predict
residual tumor has not been reported. Therefore, the aim of the
present study was to investigate the optimal cutoff value of
FDG uptake to predict residual tumor after CCRT in cervical
cancer.
Materials and Methods
Patients
From December 2005 to July 2012, 156 women with cervical
cancer were treated with CCRT in a single institute. The
inclusion criteria of this study were (1) biopsy-proven cervical
squamous cell cancer, (2) PET/CT performed before and after
treatment, and (3) no contraindications for CCRT. The exclu-
sion criteria were (1) having PET/CT performed at outside
hospitals, (2) history of prior surgery or chemotherapy, and (3)
inability to undergo PET/CT. Accordingly, a total of 136
patients (median age 57.1 years, range 27-82 years) were
enrolled in our study group. Five patients were excluded
because PET/CT images were obtained from an outside hos-
pital, and 15 patients were excluded because of inappropriate
SUV measurement. All patients signed a written informed
consent form for the 18F-FDG PET/CT scan, and the present
study was approved by the Institutional Review Board of our
medical center.
All patients also underwent a PET/CT scan, serum squa-
mous cell carcinoma antigen (SCC) level check, and PAP
smear before and after CCRT. Final treatment response was
determined by MRI and further follow-up PET/CT. One hun-
dred four of 136 patients underwent pelvic MRI before and
after CCRT, and median interval from post-treatment PET/CT
to post-treatment MRI was 1.6±1.4 weeks. Thirty-two of 136
patients underwent further follow-up PET/CT instead of MRI,
and median interval from post-treatment PET/CT to further
follow-up PET/CT was 4.1±1.3 months. During this period,
no therapy was performed. Patients were classified into two
categories: patients with residual tumor and patients without
residual tumor (complete responder). On MRI, the tumor was
evaluated based on the T2-weighted image (WI): no high
signal intensity in the cervix on T2WI was considered as no
residual tumor; high signal intensity in the cervix on T2WI
with enhancement was considered as residual tumor [16]. On
further follow-up PET/CT, no discernible FDG uptake in the
cervix was considered as no residual tumor, while discernible
increased uptake in the cervix was considered as residual
tumor by visual analysis.
PET/CT Images and Image Analysis
For PET/CT, patients fasted for at least 6 h before intravenous
injection of 18F-FDG. Approximately 5.5 MBq of 18F-FDG
per kilogram of body weight was administered intravenously,
and the duration of the uptake phase was 60 min. FDG PET
image acquisition was performed using a Biograph TruePoint
40 PET/CT scanner (Siemens Medical Systems, CTI, Knox-
ville, TN, USA), with an axial field of view of 21.6 cm and a
spatial resolution of 4.2 mm in full width at half maximum at
1 cm from the center. A low-dose CT scan for attenuation
correction was obtained, immediately followed by emission
imaging from the neck to thigh in three-dimensional mode at
3 min per bed position. The patient then underwent a
Table 1 Clinical characteristics of patients (n=136)
Characteristic Number of patients (%)
FIGO stage
IB1 2 (1.4)
IB2 1 (0.5)
IIA 5 (3.7)
IIB 97 (71.3)
IIIA 2 (1.4)
IIIB 15 (11)
IVA 7 (5.1)
IVB 7 (5.1)
Histology
Squamous cell carcinoma 124 (91.2)
Adenocarcinoma 9 (6.6)
Other 3 (2.2)
Age Median 57.1 (range 27-82)
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diagnostic CT scan with intravenous contrast. PET data
were reconstructed iteratively using an ordered-subset
expectation maximization algorithm, with low-dose CT
data sets used for attenuation correction. Images were
analyzed by two nuclear medicine physicians. For eval-
uation of cervical cancer, 18F-FDG uptake of the tumor
was measured before and after CCRT. The localization
of cervical cancer on the PET/CT was determined based
on a comparison of clinical findings, contrast-enhanced
CT findings, and MRI findings. SUVmax and SUVmean
of cervical cancer before and after CCRT were com-
pared between patients with residual tumor and patients
without residual tumor.
Statistical Analysis
Continuous variables are displayed as mean±SD, and cate-
gorical variables are displayed as counts and percentages. The
optimal cutoff value of SUV in predicting residual tumor was
determined using ROC analysis. SUV and SCC levels were
compared using the unpaired Student’s t-test. Statistical anal-
yses were carried out with SPSS software (version 20.0,
SPSS, Chicago, IL, USA), and a p -value of<0.05 was con-
sidered statistically significant.
Results
Table 1 presents the patient characteristics. The median inter-
val from the end of CCRT to post-treatment PET/CTwas 47±
39 days. Before CCRT, the average SUVmax and SUVmean
of cervical cancer were 13.5±7.1 and 7.7±4.7, respectively.
After CCRT, the SUVmax and SUVmean of cervical cancer
were 2.6±1.4 and 2.1±0.9, respectively. Before and after the
CCRT, the average levels of serum SCC were 15.6±34.3 and
1.8±2.5, respectively.
Table 2 Results for SUVmax,
SUVmean, and serum SCC level
pre- and post-treatment
Patients with
complete response (n=124)
Patients with
residual tumor (n=12)
Pre-treatment SUVmax 12.7±6.1 18.4±1.1 NS
SUVmean 7.2±4.2 12.8±6.9 p <0.001
SCC (ng/ml) 14.2±2.9 30.0±6.8 NS
Post-treatment SUVmax 2.5±0.8 5.7±2.6 p <0.001
SUVmean 1.9±0.7 3.7±1.7 p <0.001
SCC (ng/ml) 1.6±2.2 3.6±4.2 NS
(a) (c)
(e)(b) (d)
Fig. 1 Axial images of contrast-enhanced abdominal CT (a) and PET
(b) show an enhancing uterine cervical mass with FDG uptake (SUVmax
15.9). After CCRT, axial images of contrast-enhanced abdominal CT (c)
and PET (d) show decreased size of the cervical mass with SUVmax 2.7.
Sagittal T2-weighted image ofMRI shows nomass in the cervix with low
cervical signal intensity. Colposcopy and PAP smear results were nega-
tive for malignancy
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Of the 136 patients, 124 showed complete response on the
further follow-up studies; 12 of 136 patients showed residual
tumor. The post-treatment average SUVmax, pre-/post-treatment
average SUVmean, and serum SCC levels of the patients with
complete response were significantly lower than those with
residual tumor: 2.4±0.9, 7.4±4.3/1.9±0.7, and 12.9±28/1.7±
2.2, respectively, for patients with complete response; 5.3±3.4,
11.9±6.8/3.6±1.9, and 46.8±68/3.3±4.2, respectively, for pa-
tients with residual tumor (p<0.05) (Table 2). The pre-treatment
average SUVmax and pre-/post-treatment serum SCC levels of
the patients with complete response tended to be lower than those
with residual tumor: 12.7±6.1 and 14.2±2.9/1.6±2.2, respec-
tively, for patients with complete response; 18.4±1.1 and 30.0±
6.8/3.6±4.2, respectively, for those with residual tumor (p<0.5).
Fifty-two of 136 patients showed persistent FDG uptake in
the cervix equal to or higher than SUVmax 2.5, the usually
accepted cutoff level for malignancy, on post-treatment PET/
CT. Of 54 patients with persistent FDG uptake, 42 patients did
not reveal any evidence of residual tumor in the further studies
(Fig. 1). Only 12 of 54 patients revealed residual tumor in the
further studies; the specificity and positive predictive value were
low using a cutoff SUVmax of 2.5: 66% and 22%, respectively.
In ROC analyses, an optimal cutoff value of SUVmax 4.0 on
post-treatment PET/CT yielded sensitivity, specificity, positive
predictive value, and negative predictive value of 92 %, 95 %,
61 %, and 99 %, respectively. The area under the curve was
0.974 (p <0.001) (Fig. 2). Eighteen of 136 patients showed
persistent FDG uptake above SUVmax 4.0 in the cervix in
post-treatment PET/CT. Eleven of 18 patients with FDG uptake
equal to or higher than 4.0 showed residual tumor in the further
studies (Fig. 3). Seven of 18 patients showed no residual tumor in
the cervix. The differing values between the 11 patients with
residual tumor and 7 patients without residual tumor are present-
ed in Table 3. Most of the 118 patients with FDG uptake below
SUVmax 3.9 did not show residual tumor in the cervix, except
for one patient; SUVmax of this patient was 3.5 (Fig. 4).
Discussion
Predictors of disease recurrence in cervical cancer include not
only the clinical stage and lymph node status at the time of
Fig. 2 ROC curve for SUVmax and treatment response (area under
curve, 0.974; p <0.001)
(a) (c)
(b) (d)
Fig. 3 Axial images of contrast-
enhanced abdominal CT (a) and
PET (b) show an enhancing
uterine cervical mass (SUVmax
30.6). After CCRT, axial images
of contrast-enhanced abdominal
CT (c) and PET (d) show
decreased size of the cervical
mass (SUVmax 5.4). THe punch
biopsy result was positive for
malignancy
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initial diagnosis, but also tumor response after treatment [17,
18]. The 5-year survival outcome of patients with no appre-
ciable tumor was 76 % compared to 42 % for those with
findings suggestive of a tumor and 8 % for those with a
persistent tumor [8]. Post-therapeutic tumor burden change
is an important feature in cancer therapeutics. Current con-
ventional radiologic imaging techniques rely on identifying a
change in tumor dimension to evaluate therapeutic response
[9]. However, biological and molecular changes that occur
early in responders usually precede these anatomical size
changes [19, 20]. For predicting therapeutic response in cer-
vical cancer, several studies using 18F-FDG PET imaging
have shown promising results. Grigsby et al. reported three
findings: (1) a complete metabolic response on PET was
predictive of good survival (92% 5-year survival); (2) a partial
metabolic response (persistent, abnormal FDG uptake) was
predictive of poor survival (46 % 5-year survival); (3) pro-
gressive disease (new sites of abnormal FDG uptake) was
predictive of death from cervical cancer (p <0.001) [14].
Schwarz et al. demonstrated in a prospective cohort study that
post-treatment FDG uptake was predictive of survival; the 3-
year progression-free survival rates of patients with metabolic
complete response, persistent FDG uptake in the irradiated
region, and new sites of FDG uptake outside of the initial
irradiated region were 78, 33, and 0 %, respectively (p <
0.001) [15]. However, the authors of the aforementioned two
studies only reported the survival rate. They did not compare
the metabolic response with results obtained using other tech-
niques, such as MRI or histology, to confirm treatment re-
sponse, nor did they did present a definition of ‘residual FDG
uptake’ for partial metabolic response.
In our experience, the majority of patients with mild to
moderate FDG uptake after CCRT were revealed to have no
residual tumor in the cervix. However, to our knowledge, no
study has suggested a cutoff value of SUVmax on post-
treatment PET/CT for predicting residual tumor. Therefore,
in our study, an ROC curve was calculated for an optimal
cutoff value of SUVmax in post-treatment PET/CT to predict
residual cervical tumor. The results of the present study indi-
cate that post-treatment PET/CT may provide an important
Table 3 Results for SUVmax,
SUVmean, and serum SCC level
pre- and post-treatment for pa-
tients with FDG uptake equal to
or higher than 4.0
Patients with
complete response (n=7)
Patients with
residual tumor (n=11)
Pre-treatment SUVmax 12.0±3.9 19.3±10.9 NS
SUVmean 8.8±3.2 13.3±6.9 NS
SCC (ng/ml) 7.7±10.3 32.3±71.0 NS
Post-treatment SUVmax 4.4±0.4 5.9±2.7 NS
SUVmean 2.9±0.5 3.8±1.8 NS
SCC (ng/ml) 0.6±0.3 3.9±4.3 p <0.05
(a) (c)
(b) (d) (e)
Fig. 4 Axial images of contrast-enhanced abdominal CT (a) and PET
(b) show an enhancing uterine cervical mass (SUVmax 8.5). After CCRT,
axial images of contrast-enhanced abdominal CT (c) and PET (d) show
decreased size of the cervical mass (SUVmax 3.5). Sagittal T2-weighted
image of MRI shows a residual cervical mass with relatively high signal
intensity. PAP smear results were positive for malignancy
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and reliable method for the prediction of residual tumor
in the cervix with a cutoff value of SUVmax 4.0. The
specificity and positive predictive value of the cutoff
value of SUVmax 4.0 were higher than those of the
cutoff value of SUVmax 2.5, which is the usually
accepted cutoff value for malignancy (95 % and 61 %
versus 66 % and 22 %, respectively). Higher FDG
uptake in the cervix after CCRT is likely due to
radiation-related inflammation. FDG activity tends to
show an initial increase followed by a steady decline
after irradiation. Early increase of FDG uptake may be
due to acute inflammation in normal tissue caused by
irradiation or due to elevated metabolic activity in tu-
mor cells. The later decrease in FDG uptake is caused
by a decreased viable tumor cell number or reduced
tumor metabolism [21]. Another study suggests that
although tumors will show a complete metabolic re-
sponse at the completion of chemoradiation, some tu-
mors will show continued therapeutic response even
after therapy has been completed [22].
Only 1 of 118 patients with FDG uptake less than 4.0
showed residual tumor on the MRI and PAP smear studies.
On the post-treatment PET/CT, the residual tumor size was
relatively small, which may result in a partial volume effect on
the measurement of SUVmax. Change of the tumor shape
may also result in a partial volume effect [23].
Seven of 18 patients with FDG uptake higher than 4.0 had
no residual tumor on further studies. Table 3 shows that only
the post-treatment serum SCC level of 11 patients with resid-
ual tumor was significantly higher than that of 7 patients
without residual tumor. The results of several studies have
indicated that serum SCC is potentially useful in monitoring
therapeutic response of cervical cancer after primary therapy
[24–26]. Persistently elevated SCC levels after completion of
therapy represent persistent tumor or progressive disease [25].
Hong et al. showed that residual induration and/or high SCC
concentration at 2-3 months after radiotherapy represents a
high risk for treatment failure [27]. Thus, in patients with
higher than SUVmax 4.0 in the cervix after CCRT, a post-
treatment high serum SCC level may help predict residual
tumor in the cervix.
There are several limitations to our study. First, because it
was a retrospective study, the post-treatment PET/CT evalua-
tions were performed at times varying from 1 to 5months after
treatment. Second, our study is a single-institution study.
Thus, our findings may not be generalized across all centers.
Third, since our patients did not undergo an operation after
CCRT, we could not confirm the pathologic treatment re-
sponse. Finally, we only measured the SUVmax and
SUVmean, which may not be adequate markers to represent
tumor biology. Further study is needed using other parameters
that can represent tumor biology, such as metabolic tumor
volume.
Conclusion
Persistent FDG uptake in 18F-FDG PET/CT after CCRT is
frequently encountered in cervical cancer, but only a few
patients evincing it have residual tumors. A higher cutoff
SUVmax than conventional criteria for cervical cancer in
post-CCRT PET/CT might help to detect residual tumor.
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